LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Начало・Списък с акции・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Затворен

СекторЗдравеопазване

19.95 1.22

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

19.65

Максимум

20.21

Ключови измерители
By Trading Economics
Приходи	4.8M -36M
Продажби	6.1M 116M
Марж на печалбата	-30.977
Служители	1,869
EBITDA	24M -31M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+173.52% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-812M 2.2B
Предишно отваряне	18.73
Предишно затваряне	19.95

Настроения в новините

By Acuity

31%

69%

101 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

28.13 / 31.12 Подкрепа & съпротива

Zai Lab Ltd ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.12.2025 г., 20:41 ч. UTC

Печалби

Значими двигатели на пазара

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4.12.2025 г., 18:14 ч. UTC

Придобивния, сливания и поглъщания

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4.12.2025 г., 17:43 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4.12.2025 г., 17:01 ч. UTC

Печалби

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.12.2025 г., 21:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.12.2025 г., 21:54 ч. UTC

Пазарно говорене

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.12.2025 г., 21:48 ч. UTC

Пазарно говорене

Scales Hits Mark With Earnings Guidance -- Market Talk

4.12.2025 г., 21:37 ч. UTC

Печалби

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4.12.2025 г., 21:36 ч. UTC

Печалби

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4.12.2025 г., 20:04 ч. UTC

Пазарно говорене

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4.12.2025 г., 19:54 ч. UTC

Пазарно говорене

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4.12.2025 г., 19:33 ч. UTC

Пазарно говорене

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4.12.2025 г., 18:58 ч. UTC

Пазарно говорене

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4.12.2025 г., 16:33 ч. UTC

Пазарно говорене

Печалби

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Zai Lab Ltd ADR Прогноза

Ценова цел

By TipRanks

173.52% нагоре

12-месечна прогноза

Среден 54.02 USD 173.52%

Висок 74 USD

Нисък 25.7 USD

Според 6 анализатори от Wall Street, предложили 12-месечна ценова цел за Zai Lab Ltd ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

6 ratings

Купи

Задържане

Продай

Според 6 анализатори, дали борсови рейтинги на Zai Lab Ltd ADR през последните 3 месеца.

Техническа оценка

By Trading Central

28.13 / 31.12Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Настроение

By Acuity

101 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.